Eupraxia Pharmaceuticals Inc. (EPRX) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-01, Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $7.25 (-1.76% 1D, market cap $477.8M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, EPRX ranks #781 in composite RQD confidence.
Within the Health Care sector (Pharmaceuticals and Biotechnology), EPRX carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SSII (SS Innovations International Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -18.5%, cap $477.2M) and BWAY (BrainsWay Ltd.) posts a C- grade (61/100 RQD, P/E N/A, ROIC —, cap $478.7M). Among the 5-stock peer group, EPRX leads on earnings multiple (N/A) while MNPR leads on capital efficiency (-17.4% ROIC).
Per EPRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001581178), Eupraxia Pharmaceuticals Inc. generated $0 in revenue, -$38.6M in net income, and -$28.6M in free cash flow against $86.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While EPRX currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.59) and Max Pain ($7.61) forces dealer call-delta covering toward $9.79.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Eupraxia Pharmaceuticals Inc. (EPRX) slipped -1.76% to $7.25, trading at 49% of its 52-week range ($5.25 – $9.32). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
VANCOUVER, British Columbia, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffu
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on EPRX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for EPRX. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Eupraxia Pharmaceuticals Inc. (EPRX) ranks #781 by composite RQD confidence (36/100, grade D-) and #462 by equity capitalization ($477.8M). Within this direct 5-issuer industry benchmark cohort, EPRX leads on earnings valuation at N/A trailing P/E, while MNPR leads on capital efficiency and profitability with -17.4% ROIC and — gross margin. BWAY currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with EPRX at 36/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| EPRX
ACTIVE
Eupraxia Pharmaceuticals Inc. | D- | 36/100 | — | — | -35.0% | -1.76% | $477.8M | Benchmark Subject |
| SSII SS Innovations International Inc. | D- | 39/100 | — | 46.0% | -18.5% | -2.46% | $477.2M | /ssii-vs-eprx → |
| BWAY BrainsWay Ltd. | C- | 61/100 | — | — | — | +4.93% | $478.7M | /bway-vs-eprx → |
| MNPR Monopar Therapeutics Inc. | E | 31/100 | — | — | -17.4% | -2.02% | $482.7M | /mnpr-vs-eprx → |
| BLSM BlossomHill Therapeutics Inc. | D | 46/100 | — | — | — | -7.59% | $483.4M | /blsm-vs-eprx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Eupraxia Pharmaceuticals Inc. (EPRX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$38.6M, operating cash flow of -$28.6M, and free cash flow of -$28.6M (+4.8% YoY). On the balance sheet, EPRX closed FY2025 with $86.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$38.6M | -$28.6M | -$28.6M | $86.2M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$25.5M | -$30.0M | -$30.0M | $34.9M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$28.2M | -$20.7M | -$20.7M | — | — |
As of 2026-11-01, Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $7.25 (-1.76% 1D, market cap $477.8M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, EPRX ranks #781 in composite RQD confidence.
Within the Health Care sector (Pharmaceuticals and Biotechnology), EPRX carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SSII (SS Innovations International Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -18.5%, cap $477.2M) and BWAY (BrainsWay Ltd.) posts a C- grade (61/100 RQD, P/E N/A, ROIC —, cap $478.7M). Among the 5-stock peer group, EPRX leads on earnings multiple (N/A) while MNPR leads on capital efficiency (-17.4% ROIC).
Per EPRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001581178), Eupraxia Pharmaceuticals Inc. generated $0 in revenue, -$38.6M in net income, and -$28.6M in free cash flow against $86.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
EPRX last traded at $7.25 (-1.76% on volume of 1,015,484 shares), positioning the stock -4.48% below its 50-day simple moving average ($7.59) and -0.82% below its 200-day simple moving average ($7.31). Across its 52-week range of $5.25 to $9.32, EPRX sits at the 49.1% percentile with a 14-day RSI of 43.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($6.34 to $8.16).
Why EPRX Stock slipped -1.76% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.